Financial Disclosures and Competing Interests
Dr Rui Wang is the principal investigator of this clinical trial. Dr Hai
Wang owns the patent of ITKL. Other authors have no financial
disclosures or conflicts of interest to report.
The authors have not received funding from any sources other than their
employing institutions, identified with the author’s affiliations. The
authors declare no other relationships or activities that might appear
to have influenced the submitted work
References
1 Wang H. Pharmacological characteristics of the novel antihypertensive
drug, iptakalim hydrochloride, and its molecular mechanisms. Drug
Development Research 2003; 58: 65-8.
2 Pan Z, Huang J, Cui W, Long C, Zhang Y, Wang H. Targeting hypertension
with a new adenosine triphosphate-sensitive potassium channel opener
iptakalim. Journal of cardiovascular pharmacology 2010; 56: 215-28.
3
<E14-Clinical-Evaluation-of-QT-QTc-Interval-Prolongation-and-Proarrhythmic-Potential-for-Non-Antiarrhythmic-Drugs.pdf>.
4 Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, et
al . The IQ-CSRC prospective clinical Phase 1 study: ”Can early QT
assessment using exposure response analysis replace the thorough QT
study?”. Annals of noninvasive electrocardiology : the official journal
of the International Society for Holter and Noninvasive
Electrocardiology, Inc 2014; 19: 70-81.
5 Kinrade SA, Mason JW, Sanabria CR, Rayner CR, Bullock JM, Stanworth
SH, et al . Evaluation of the Cardiac Safety of Long-Acting
Endectocide Moxidectin in a Randomized Concentration-QT Study. Clinical
and translational science 2018; 11: 582-9.
6 Matsukura S, Nakamura Y, Hoshiai K, Hayashi T, Koga T, Goto A,
et al . Effects of moxifloxacin on the proarrhythmic surrogate markers
in healthy Filipino subjects: Exposure-response modeling using ECG data
of thorough QT/QTc study. Journal of pharmacological sciences 2018; 136:
234-41.
7 Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, et al .
Scientific white paper on concentration-QTc modeling. Journal of
pharmacokinetics and pharmacodynamics 2018; 45: 383-97.
8 Cai Y, Chai D, Pei F, Fang Y, Wang R, Liang BB, et al .
Single-dose pharmacokinetics and safety of iptakalim hydrochloride in
Chinese healthy volunteers. The Journal of pharmacy and pharmacology
2012; 64: 337-43.
9 Tsamandouras N, Duvvuri S, Riley S. Impact of Phase 1 study design on
estimation of QT interval prolongation risk using exposure-response
analysis. Journal of pharmacokinetics and pharmacodynamics 2019; 46:
605-16.
10 Ferber G, Sun Y, Darpo B, Garnett C, Liu J. Study Design Parameters
Affecting Exposure Response Analysis of QT Data: Results From Simulation
Studies. Journal of clinical pharmacology 2018; 58: 674-85.
11 Chapel S, Hutmacher MM, Bockbrader H, de Greef R, Lalonde RL.
Comparison of QTc data analysis methods recommended by the ICH E14
guidance and exposure-response analysis: case study of a thorough QT
study of asenapine. Clinical pharmacology and therapeutics 2011; 89:
75-80.
12 Szeto V, Chen NH, Sun HS, Feng ZP. The role of K(ATP) channels in
cerebral ischemic stroke and diabetes. Acta pharmacologica Sinica 2018;
39: 683-94.
13 Yokoshiki H, Sunagawa M, Seki T, Sperelakis N. ATP-sensitive K+
channels in pancreatic, cardiac, and vascular smooth muscle cells. The
American journal of physiology 1998; 274: C25-37.
14 Foster MN, Coetzee WA. KATP Channels in the Cardiovascular System.
Physiological reviews 2016; 96: 177-252.
15 Wang Y. Analysis of Iptakalim-induced gene expression changes in
heart, brain and liver by cDNA microarray. Chinese Pharmacological
Bulletin 2007; 3.
16 Xuan ZL. Effects of iptakalim on antihypertensive effect and QT
interval dispersion in patients with hypertension. Chinese Journal of
Gerontology 2013; 17.
17 Liu W, Xiao WB, Lu XQ, Wang H. Effects of iptakalim on blood pressure
and cardiac function in rats Chinese Pharmacological Bulletin 2003:
227-9.
18 Long CL. Effects of iptakalim on blood pressure and cardiac function
in rats Chin J Clin Pharm Therap 2003; 5.
Figure 1a. Mean plasma concentration (Mean+SD) by time point and dose
level in the SAD study.
Figure 1b. Mean plasma concentration (Mean+SD) by time point and dose
level in the MAD study.
Figure 2a. The curves of ΔΔHR-time curve of all cohorts (Mean±SE).
Figure 2b. The scatter diagram of correction between QTcF and RR.
Figure 2c. The scatter diagram of correction between concentration and
ΔQTcF.
Figure 2d. The Curves of concentration/ ΔQTcF-time of all cohort
(Mean±SE).
Figure 2e. The final model GOF diagram. (The black solid line is the
standard line, and the red dotted line is the regression trend line).
Figure 3a. Δ QTcF variation over time.
Figure 3b. Δ Δ QTcF variation over time.
Figure 3c. The trend of plasma concentration versus Δ Δ QTcF. The blue
line is the predicted value of the model, and the shaded part is 90%
confidence interval.
Figure 3d. ΔΔ QTcF and its 90% CI at different doses. The blue interval
is the interval calculated by the parameter method, and the red interval
is the interval calculated by the Bootstrap method.